Tcr2 Therapeutics Inc

-0.13 (-1.94%)
Regulatory, Earnings Announcements

TCR² Therapeutics Reports Positive Interim Results from Ongoing Trial of Gavo-cel

Published: 09/17/2021 11:39 GMT
Tcr2 Therapeutics Inc (TCRR) - Tcr² Therapeutics Announces Positive Interim Results From Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-expressing Solid Tumors.
Tcr2 Therapeutics Inc - Clinical Activity Observed in All Three Mesothelin-expressing Tumor Types Treated.
Tcr2 Therapeutics Inc - Gavo-cel Disease Control Rate 81% With Tumor Regression in 15 of 16 Evaluable Patients.
Tcr2 Therapeutics - Overall Response Rate 31% in Patients Infused With Gavo-cel Following Lymphodepletion.
Tcr2 Therapeutics Inc - Meaningful Survival Benefit at 11.2 Months for Patients With Refractory Mesothelioma.
Tcr2 Therapeutics - Recommended Phase 2 Dose Being Refined After Identification of Maximum Tolerated Dose.
Tcr2 Therapeutics Inc - Gavo-cel Was Generally Well Tolerated With a Manageable Adverse Event Profile.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.64

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.71

More details on our Analysts Page.